Table 3

Overview of reasons for a BICLA non-response/SRI(4) response at week 52 in TULIP-1 among BICLA non-responders/SRI(4) responders

BICLA non-response/SRI response, n (%)SRI(4) responders/BICLA non-responders in TULIP-1
Placebo
(n=28)
Anifrolumab 300 mg
(n=12)
BICLA non-response due to rash/
SRI response due to arthritis
20 (71.4)5 (41.7)
BICLA non-response due to rash/
SRI response not due to arthritis
4 (14.3)3 (25.0)
BICLA non-response on arthritis/
SRI response due to any reason
2 (7.1)2 (16.7)
Other* BICLA non-response/
SRI response due to any reason
2 (7.1)2 (16.7)
  • *Non-response due to a clinical manifestation other than rash or arthritis.

  • BICLA, British Isles Lupus Assessment Group-based Composite Lupus Assessment; SRI(4), Systemic Lupus Erythematosus Responder Index of ≥4.